Skip to content

Head to head

Harmony XL Pro vs Lumenis One (2026)

Compare purchase costs, running costs and the evidence behind each device.

Read the comparison overview
Purchase cost
The catalog lists $60k–$110k for Harmony XL Pro. No new-price range is on file for Lumenis One. Check the source notes and request current quotes.
Technology
Harmony XL Pro: IPL. Lumenis One: Diode laser.
Practice fit
Both are listed under multi-app platform. Check each model’s US regulatory status and labeled indications for your intended use.

Multi-app platform

View full device profile →

Multi-app platform

View full device profile →

Price comparison

New price range

Alma Harmony XL Pro
$60k–$110kReported source: Dealer quote · Aug 12, 2026
Lumenis One
Not published

Used asking range

Alma Harmony XL Pro
$30k–$55kReported source: Used listing · Aug 12, 2026
Lumenis One
$8k–$18kSource not documented

Payback calculator

Alma Harmony XL Pro
View ROI calculator

Next step

Alma Harmony XL Pro
Lumenis One

Explore this model’s specs and owner reviews. For new-equipment inquiries, browse current models.

Browse current models

Consumable economics

Consumable cost / lock-in

Alma Harmony XL Pro
Supply pricing is not documented with a dated source yet. Request an itemized supply quote.
Lumenis One

Service cost

Alma Harmony XL Pro
Not published
Lumenis One
Not published

FDA clearance

FDA status & indication

Alma Harmony XL Pro
Read FDA indication wording
[…] 540-950 nm VL/PL, VP, and SSR Module AFT Handpieces: The Advanced Fluorescence Technology (AFT) 540-950 nm VL/PL, VP, and SSR Module handpieces (with and without contact-cooling) are indicated for: The treatment of moderate inflammatory acne vulgaris. The treatment of benign pigmented epidermal lesions including dyschromia, hyperpigmentation, melasma, and ephelides (freckles), lentigines, nevi, melasma, and café-au-lait macules. The treatment of cutaneous lesions including warts, scars and striae. The treatment of benign cutaneous vascular lesions including port wine stains, hemangiomas, facial, truncal and leg telangiectasias, rosacea, erythema of rosacea, angiomas and spider angiomas, poikiloderma of Civatte, leg veins and venous malformations. The removal of unwanted hair to effect stable long-term or permanent hair reduction. Use on all skin types (Fitzpatrick I-VI). 570-950 nm SR Module AFT Handpiece: The Advanced Fluorescence Technology (AFT) 570-950 nm SR Module handpiece (with and without contact-cooling) is indicated for: The treatment of moderate inflammatory acne vulgaris. The treatment of benign pigmented epidermal lesions, including dyschromia, hyperpigmentation, melasma and ephelides (freckles). The treatment of face and body vascular and pigmented lesions. The treatment of cutaneous lesions, including scars and striae. The treatment of benign cutaneous vascular lesions, including port wine stains, hemangiomas, facial, truncal and leg telangiectasias, rosacea, melasma, angiomas and spider angiomas, poikiloderma of Civatte, leg veins and venous malformations. The removal of unwanted hair to effect stable long-term or permanent hair reduction. Use on all skin types (Fitzpatrick I-VI).
Lumenis One
FDA ClearedK030342
Read FDA indication wording
The Lumenis Family of Intense Pulsed-Light (IPL) and IPL/Nd:YAG laser systems (and the delivery accessories that are used with them to deliver light and/or laser energy) are indicated for use in surgical, aesthetic and cosmetic applications requiring selective photothermolysis (photocoagulation or coagulation) and hemostasis of soft tissue in the medical specialties of general and plastic surgery, and dermatology. Intense Pulsed Light Energy/ Wavelengths (515 - 1200 nm) are indicated for: * The treatment of tattoos and benign pigmented epidermal and cutaneous lesions including warts, scars and striae; LUMENIS, fNC. MODIFICATIONTO IPL AND I P W D : Y A G COMB~NAT~ONPRODUCTFAMIUES CONFlDENTIAL 6 2 V. VI. * The treatment of benign cutaneous vascular lesions, including port wine stains, hemangiomas, facial, truncal and leg telangiectasias, rosacea, melasma, angiomas and spider angiomas, poikiloderma of Civatte, leg veins and venous malformations; The removal of unwanted hair from all skin types, and to effect stable long-term, or permanent2, hair reduction in skin types I-V through selective targeting o f melanin in hair follicles. * Nd:YAG Laser Wavelength (1064 nm) is indicated for the coagulation and hemostasis of vascular lesions and soft tissue, including: * Treatment and clearance of superficial and deep telangectasias (venulectasias)and reticular veins (0.1 - 4.0 mm diameter) of the leg. The removal of unwanted hair from all skin types, and to effect stable long-term, or permanent2, hair reduction in skin types I-V through selective targeting of melanin in hair follicles.

Which chains run each

Chain adoption

Alma Harmony XL Pro
0 recorded pairings
Lumenis One
0 recorded pairings

Chains using it

Alma Harmony XL Pro
Lumenis One

Approved reviews

Alma Harmony XL Pro
0
Lumenis One
0

Specs and platform

Manufacturer

Alma Harmony XL Pro
Alma
Lumenis One
Lumenis

Built by (OEM)

Alma Harmony XL Pro
Alma Lasers Ltd.
Lumenis One
Lumenis Be Ltd.

Category

Alma Harmony XL Pro
Multi-app platform
Lumenis One
Multi-app platform

Technology

Alma Harmony XL Pro
AFT IPL + multiple laser modules (IPL)
Lumenis One
Universal IPL + 1064 + LightSheer diode (Diode laser)

Launch year

Alma Harmony XL Pro
2015
Lumenis One
2003

Status

Alma Harmony XL Pro
Current
Lumenis One
Legacy-used-market

Manufacturer source record

Alma Harmony XL Pro
No linked source on file.
Lumenis One
No linked source on file.

Current alternatives

Current catalog models in related categories. Confirm availability and configuration with the supplier.

Device and company names are trademarks of their respective owners. The Aesthetic Index is not affiliated with or endorsed by any manufacturer, distributor or lender named here, except as disclosed. Price figures are references, not current offers. Check each device’s source notes. Not medical, legal or regulatory advice.